- Email: [email protected]
5567316 Process for recovering metals from solution utilizing metalloprotein affinity chromatography
PATENT ABSTRACTS
Atroporin and Kaotree, respectively. The cancer cell inhibitors Atroporin and Kaotree are characterized as potent anti cancer agents. Atroporin and Kaotree, individually, or combined together selectively kill various types of cancer cells in concentrations as low as 0.5 mug/ml. Atroporin and Kaotree are characterized as stable protein components of venoms consisting of peptides whose molecular weights axe approximately 35,000 and 6,000 daltous, revealed by gel electrophoresis. The partial sequence of Atroporin for its fast fifteen N-terminal amino acids is:(*See Patent for Tabular Presentation*) PS and, similarly for Kaotree:(*See Patent for Tabular Presentation*) PS Neither of these sequences appear in standard data bases including all known proteins, therefore they are novel proteins. Atroporin and Kaotree have cytolytic, i.e. killing effect, on various types of cancer ceils and are claimed as versatile anti cancer agents. Furthermore, Atroporin and Kaotree are claimed as therapeutic agents for a wide range of cancers such as: breast, colon, liver, lung pharynx ovary etc. It is also an object of this invention to provide two different embodiments such as Atroporin and Kaotree, or the combination of both, as compositions for the treatment of various types of cancers as a biotherapy.
5565549 CD8+ CELL ANTIVIRAL FACTOR Levy Jay; Mackewicz Carl San Francisco, CA, UNITED STATES Assigned to The Regents Of The University Of California A protein secretezi by peripheral blood mononuclear cells and specifically from CD8+ lyphocytes is purified and characterized here and designated CD8+ cell antiviral factor (CAF). The CAF is lipid free, has a molecular weight of less than 30,000 and has been found to inhibit the replication of retroviroses and in particular to inhibit the replication of HIV-1, HIV-2, and SIV. CAF can be used to inhibit viral RNA transcription which inhibits viral replication. Accordingly, CAF can be used to treat patients infected with retroviroses. The CAF can also generate antibodies which can be used to create assay reagents for detecting CAF in a body fluid and on the surface of CDS+ cells to determine the condition of an HIV infected individual.
465
5567316 PROCESS METALS UTILIZING
FOR RECOVERING FROM SOLUTION METALLOPROTEIN AFFINITY CHROMATOGRAPHY
Spears Dennis R; Vincent John B Tuscaloosa. AL, UNITED STATES Assigned to The United States of America as represented by the Secretary of the Interior A process for recovering metals from an aqueous metal-ion beating solution includes the steps of: (a) forming an affinity chromatography matrix by providing a metal beating protein bound to an insoluble support material to form an immobilized metalloprotein material; Co) introducing into the affinity chromatography matrix a quantity of aqueous metal-containing solution having a pH, redox potential or other property properly adjusted to cause ions of a selected metal entrained within the solution to bind to the immobilized metalloprotein material; (c) washing the matrix with a first buffer which does not elute the metal ions of interest but does remove other species of metal enWained in the solution; and (d) applying a second buffer or solution of appropriate pH, redox potential or other property to the affinity chromatography matrix to elute the metal ions of interest from the immobilized metalloprotein material.
5567317 METHOD TO IDENTIFY ANALYTE-BINDING LIGANDS Kauvar Lawrence M San Francisco, CA, UNITED STATES Assigned to Terrapin Technologies inc The invention provides methods to obtain panels of low molecular weight polymers resulting from varying constituent monomers, which panels are systematically diverse with respect to two or more variables. The panels can be screened for members (paralogs) which are capable of specifically binding a target moiety. Such paralogs are useful for chromatogaphic separations and purifications of desired analytes and in binding assays, such as immunc~ssays,
Atroporin and Kaotree, respectively. The cancer cell inhibitors Atroporin and Kaotree are characterized as potent anti cancer agents. Atroporin and Kaotree, individually, or combined together selectively kill various types of cancer cells in concentrations as low as 0.5 mug/ml. Atroporin and Kaotree are characterized as stable protein components of venoms consisting of peptides whose molecular weights axe approximately 35,000 and 6,000 daltous, revealed by gel electrophoresis. The partial sequence of Atroporin for its fast fifteen N-terminal amino acids is:(*See Patent for Tabular Presentation*) PS and, similarly for Kaotree:(*See Patent for Tabular Presentation*) PS Neither of these sequences appear in standard data bases including all known proteins, therefore they are novel proteins. Atroporin and Kaotree have cytolytic, i.e. killing effect, on various types of cancer ceils and are claimed as versatile anti cancer agents. Furthermore, Atroporin and Kaotree are claimed as therapeutic agents for a wide range of cancers such as: breast, colon, liver, lung pharynx ovary etc. It is also an object of this invention to provide two different embodiments such as Atroporin and Kaotree, or the combination of both, as compositions for the treatment of various types of cancers as a biotherapy.
5565549 CD8+ CELL ANTIVIRAL FACTOR Levy Jay; Mackewicz Carl San Francisco, CA, UNITED STATES Assigned to The Regents Of The University Of California A protein secretezi by peripheral blood mononuclear cells and specifically from CD8+ lyphocytes is purified and characterized here and designated CD8+ cell antiviral factor (CAF). The CAF is lipid free, has a molecular weight of less than 30,000 and has been found to inhibit the replication of retroviroses and in particular to inhibit the replication of HIV-1, HIV-2, and SIV. CAF can be used to inhibit viral RNA transcription which inhibits viral replication. Accordingly, CAF can be used to treat patients infected with retroviroses. The CAF can also generate antibodies which can be used to create assay reagents for detecting CAF in a body fluid and on the surface of CDS+ cells to determine the condition of an HIV infected individual.
465
5567316 PROCESS METALS UTILIZING
FOR RECOVERING FROM SOLUTION METALLOPROTEIN AFFINITY CHROMATOGRAPHY
Spears Dennis R; Vincent John B Tuscaloosa. AL, UNITED STATES Assigned to The United States of America as represented by the Secretary of the Interior A process for recovering metals from an aqueous metal-ion beating solution includes the steps of: (a) forming an affinity chromatography matrix by providing a metal beating protein bound to an insoluble support material to form an immobilized metalloprotein material; Co) introducing into the affinity chromatography matrix a quantity of aqueous metal-containing solution having a pH, redox potential or other property properly adjusted to cause ions of a selected metal entrained within the solution to bind to the immobilized metalloprotein material; (c) washing the matrix with a first buffer which does not elute the metal ions of interest but does remove other species of metal enWained in the solution; and (d) applying a second buffer or solution of appropriate pH, redox potential or other property to the affinity chromatography matrix to elute the metal ions of interest from the immobilized metalloprotein material.
5567317 METHOD TO IDENTIFY ANALYTE-BINDING LIGANDS Kauvar Lawrence M San Francisco, CA, UNITED STATES Assigned to Terrapin Technologies inc The invention provides methods to obtain panels of low molecular weight polymers resulting from varying constituent monomers, which panels are systematically diverse with respect to two or more variables. The panels can be screened for members (paralogs) which are capable of specifically binding a target moiety. Such paralogs are useful for chromatogaphic separations and purifications of desired analytes and in binding assays, such as immunc~ssays,